<DOC>
	<DOC>NCT02064816</DOC>
	<brief_summary>This is an open-label, multi-center, 12-week, randomized, controlled, parallel group, Phase 4 study to assess whether the morning administration of interferon beta 1a (Rebif®) leads to a lower severity of flu-like symptoms (FLS) as compared to the evening administration, in subjects with relapsing multiple sclerosis (RMS).</brief_summary>
	<brief_title>A Study of Rebif® in Subjects With Relapsing Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<criteria>Males and females between 18 and 60 years of age Female subjects must be neither pregnant nor breastfeeding and must lack childbearing potential. Furthermore, female subjects must not have been pregnant from at least three months prior to enter in the study Subjects have RMS according to the revised McDonald Criteria (2010) Subjects with an expanded disability status scale (EDSS) score of less than 6.0 Subjects naive to treatment and eligible for treatment with Rebif® 44 three times a week, or patients having received glatiramer acetate with a washout from at least one month, or patients having received treatment with natalizumab or fingolimod with a washout from at least three months Subjects able to selfinject treatment using RebiSmart® Subjects willing and able to comply with the protocol for the duration of the study Subjects have given written informed consent to take part in the study Subjects have any disease other than MS that could better explain his/her signs and symptoms Subjects who have received any immunosuppressive agents within 3 months prior to Baseline Subjects who have received any corticosteroids within 30 days prior to Baseline Subjects have a MS relapse within 30 days prior to Baseline Subjects have inadequate liver function and bone marrow reserve as defined in the protocol Subjects have moderate to severe renal impairment Subjects have any visual or physical impairment that precludes the subjects from selfinjecting the treatment using RebiSmart® Subjects have hypersensitivity to natural or recombinant interferon, or to any of its excipients Subjects have any contraindications to treatment with interferon (IFN) beta 1a according to Summary of Product Characteristics (SmPC) Subjects have any contraindications to treatment with ibuprofen/paracetamol according to SmPC Obese subjects, defined by body mass index greater than 30 kilogram per square meter (kg/m^2) Subjects have participated in any other investigational trial within 30 days from Baseline Subjects have any other significant disease that in the Investigator's opinion would exclude the subject from the trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Multiple Sclerosis, Relapsing-Remitting</keyword>
	<keyword>Interferon beta 1a</keyword>
	<keyword>Rebif®</keyword>
</DOC>